On Thursday, August 6, 2026, Grupo Fleury (FLRY3) reported net income of R$ 221.9 million in the second quarter of 2026 (2Q26), an increase of 45.7% compared to 2Q25, with a net margin of 9.6%. In the period, gross revenue reached R$ 2.5146 billion, up 14.4%, while net revenue totaled R$ 2.3167 billion, also 14.4% higher than the previous year.
EBITDA (earnings before interest, taxes, depreciation and amortization) was R$ 612.9 million in 2Q26, an increase of 15.2% year over year, with a margin of 26.5%. Gross profit reached R$ 644.1 million, an advance of 22%, and the gross margin rose to 27.8%. The company also reported that return on invested capital (ROIC) reached 17.8% in the last 12 months.
By segment, gross revenue from B2C diagnostic medicine grew 15.0% in the quarter to R$ 1.7677 billion, with highlights for the Fleury brand, which advanced 12.0%, and for the other São Paulo brands, up 27.7% (12.9% organic). The operation in Minas Gerais increased 19.2% (14.3% organic), Rio de Janeiro grew 8.9% and the regional brands, 10.2%. The B2B business, which includes Lab-to-Lab and hospitals, recorded gross revenue of R$ 545.1 million, up 12.2%, while New Elos totaled R$ 201.8 million, an advance of 15.9% and an 8.0% share of revenue.
In 2Q26, the financial result was an expense of R$ 111.3 million, a reduction of 5.7% compared to 2Q25 in nominal terms and a drop of 102 basis points relative to net revenue. The effective income tax and social contribution rate was 21.8%, lower than the 23.5% of the previous year, which contributed to the increase in net income.
Regarding the capital structure, net debt ended June 2026 at R$ 2.4225 billion, with net debt/EBITDA for the last 12 months at 1.1x, the same level as a year earlier. Capex totaled R$ 75.7 million in the quarter, a decline of 46.5% compared to 2Q25, with a lower volume of investments in IT and digital and a greater focus on expanding the supply and capacity of technical areas.
